Literature DB >> 2382661

Autoantibodies in alcoholic liver disease.

C A Laskin1, E Vidins, L M Blendis, C A Soloninka.   

Abstract

PURPOSE: To test the hypothesis that since only a proportion of heavy drinkers develop significant alcoholic liver disease (ALD), an autoimmune pathogenesis is likely. PATIENTS AND METHODS: Autoimmune markers were measured in 47 patients with biopsy-proven ALD and compared to measurements in 20 alcoholics without clinical and hematologic evidence of ALD and 28 patients with autoimmune chronic active hepatitis (CAH).
RESULTS: Twenty-two percent of patients with ALD were antinuclear antibody-positive, compared to 71% of patients with CAH. Approximately 60% of patients with ALD had either anti-single-stranded or anti-double-stranded DNA antibodies, slightly more than the patients with CAH. Another marker of autoimmunity, as in systemic lupus erythematosus, is the presence of IgM antibodies to autologous and heterologous lymphocytes, which are cytotoxic at 4 degrees C. Seventy-two percent of patients with CAH had positive antilymphocyte antibodies, compared to 59.6% of patients with ALD. Furthermore, more than 90% of the sera from ALD and CAH patients displayed lymphocytotoxicity. Thirty-two percent and 25.5% of CAH and ALD patients, respectively, had all three autoantibodies present.
CONCLUSION: These results suggest that autoimmune mechanisms may indeed play a role in the pathogenesis of ALD in at least some patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2382661     DOI: 10.1016/0002-9343(90)90288-o

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  13 in total

1.  Autoimmune hepatitis induced by syngeneic liver cytosolic proteins biotransformed by alcohol metabolites.

Authors:  Geoffrey M Thiele; Michael J Duryee; Monte S Willis; Dean J Tuma; Stanley J Radio; Carlos D Hunter; Courtney S Schaffert; Lynell W Klassen
Journal:  Alcohol Clin Exp Res       Date:  2010-09-22       Impact factor: 3.455

Review 2.  Clinical immunology.

Authors:  R J Powell
Journal:  Postgrad Med J       Date:  1991-11       Impact factor: 2.401

3.  Autoimmune Markers Do Not Impact Clinical Presentation or Natural History of Steatohepatitis-Related Liver Disease.

Authors:  Sujan Ravi; Mohamed Shoreibah; Evan Raff; Joseph Bloomer; Donny Kakati; Khalid Rasheed; Ashwani K Singal
Journal:  Dig Dis Sci       Date:  2015-07-15       Impact factor: 3.199

4.  Performance parameters of the conventional serological markers for autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-12-03       Impact factor: 3.199

5.  Liver tissue metabolically transformed by alcohol induces immune recognition of liver self-proteins but not in vivo inflammation.

Authors:  Michael J Duryee; Benjamin M Wiese; Jordan R Bowman; Jared D Vanlandingham; Lynell W Klassen; Geoffrey E Thiele; Carlos D Hunter; Daniel R Anderson; Ted R Mikuls; Geoffrey M Thiele
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-12-28       Impact factor: 4.052

6.  Are antibodies to carbonic anhydrase II specific for anti-mitochondrial antibody-negative primary biliary cirrhosis?

Authors:  D Comay; K Cauch-Dudek; D Hemphill; E Diamandis; I Wanless; E J Heathcote
Journal:  Dig Dis Sci       Date:  2000-10       Impact factor: 3.199

Review 7.  A recent perspective on alcohol, immunity, and host defense.

Authors:  Gyongyi Szabo; Pranoti Mandrekar
Journal:  Alcohol Clin Exp Res       Date:  2008-12-02       Impact factor: 3.455

Review 8.  The role of active metabolites in drug toxicity.

Authors:  M Pirmohamed; N R Kitteringham; B K Park
Journal:  Drug Saf       Date:  1994-08       Impact factor: 5.606

9.  In vitro acetaldehyde formation by human colonic bacteria.

Authors:  K Jokelainen; R P Roine; H Väänänen; M Färkkilä; M Salaspuro
Journal:  Gut       Date:  1994-09       Impact factor: 23.059

10.  Immune mechanisms in alcoholic liver disease.

Authors:  Emanuele Albano; Matteo Vidali
Journal:  Genes Nutr       Date:  2009-10-07       Impact factor: 5.523

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.